drugset / Trial / NCT05891158
A Study About Fazirsiran in People With and Without Liver Problems
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main aim of this study is to learn how the body processes fazirsiran (pharmacokinetics \[PK\]) in people with mild, moderate, or severe liver problems, compared to people with normal liver function. The study will include participants with liver scarring (cirrhosis) and mild, moderate, or severe liver problems, and participants with normal liver function. All participants will be given 1 injection of fazirsiran and will be followed up for 6 months after the fazirsiran injection.
Timeline
- Start
- 2023-10-05
- Primary completion
- 2025-09-03
- Completion
- 2025-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fazirsiran | Unknown | 200 mg | Subcutaneous |
Indications
No indication recorded.